Home > Newsletters > FDAnews Device Daily Bulletin > Device Classification Stand Off With Software Developer Warrants Warning
FDAnews Device Daily Bulletin
June 1, 2012 | Vol. 9 No. 108
Device Classification Stand Off With Software Developer Warrants Warning
The FDA has escalated a long-simmering dispute with Israeli-owned software developer NeuroTrax about the proper classification for its MindStreams cognitive health assessment tool, telling the company in a warning letter it must seek Class III status or halt marketing the product. NeuroTrax is marketing its MindStreams software without marketing clearance or approval by the FDA, which has determined the product to be a Class III device posing heightened risk to patients, the agency said in a March 15 warning letter posted April 3.
The GMP Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.